Significance
Oligomerization and GAG binding are key regulatory steps for many extracellular ligands. Our analyses provide a structural basis of CCL5 and CCL3 oligomerization and explain how oligomerization affects the interaction of these chemokines with GAG and their functions. Our GAG-bound chemokine structures reveal how CCL5 and CCL3 oligomerization creates distinctive GAG-binding grooves to enhance GAG binding via avidity for regulating chemokine functions. Furthermore, our CCL5 structure may explain how CXCL4, a CXC chemokine, heterooligomerizes with CCL5 to modulate chemokine-mediated activities.
Together, these data provide new structural insights into how oligomerization and GAG binding are coupled to regulate functions of CC chemokines and offer novel pharmacophores for the design of therapeutics for treating chemokine-mediated human diseases.
\body Introduction CC chemokines are a 28-member family of 8-14 kDa small molecular weight (MW) chemotactic cytokines with crucial roles in inflammation and infection (1, 2) . Chemokine oligomerization and their interaction with glycosaminoglycans (GAGs), polysaccharides that are either free or attached to proteoglycans mostly on cell surface or in the extracellular matrix, is a coupled process that play key roles in chemokine functions (3) (4) (5) (6) (7) (8) . These include, but are not limited to, protection from proteolysis, regulation of chemotactic/haptatactic gradients to guide cell migration, transcytosis of chemokines across cells, and presentation to surface receptors of target cells, particularly under flow conditions. Most CC chemokines readily dimerize by themselves, and form higher MW complexes in the presence of GAGs (4) . CCL3
(MIP-1α), CCL4 (MIP-1β), and CCL5 (RANTES) are CCR5 ligands that are involved in diverse proinflammatory responses and are targeted for therapeutic innovations for human diseases including cancer, cardiovascular diseases, and HIV infection (9) (10) (11) (12) . Unlike other CC chemokines, these chemokines reversibly self-assemble into high MW oligomers, up to >600 kDa in size (13, 14) . The presence of GAGs further modulates the oligomerization of these chemokines. Mutants of these chemokines with reduced oligomerization have chemotactic activity comparable to wild type chemokines (15, 16) . However, such mutants make CCL3, CCL4, and CCL5 less effective at recruiting cells into the mouse peritoneum (14, 17, 18) . CCL5 mutants defective in oligomerization fail to block HIV infection and induce the expression of interferon-γ and CCL4 (15, 19) . Normally, CCL5 can trigger CCR5-dependent apoptosis and GPCR-independent MAP kinase activation via CD44, but CCL5 mutants defective in either oligomerization or GAG binding fail to elicit these responses (20, 21) . Manipulation of CCL3 oligomerization by mutation has led to the development of CCL3-based cancer therapies that preserve stem cells and boost immune therapy (11, 12, 22) .
Accumulating evidence indicates that oligomerization of CC chemokines occurs in vivo.
For example, CCL5 is released from T cells as high MW, GAG-bound complexes (23) and filamentous CCL5 oligomers are found on vascular endothelial cells in a GAG-dependent manner (24) . However, significant gaps exist in our understanding of the structural basis of CC chemokine oligomerization and GAG binding. While CCL3, CCL4, and CCL5 oligomerize readily under physiological conditions, only CCL3 and CCL4 oligomer structures are available at a neutral pH (14) (Table S1 ). All available CCL5 structures were determined at acidic pH (25) (26) (27) (28) (29) (30) (Table S1 ). Unfortunately, none explain how CCL5 mutations profoundly affect CCL5 oligomerization and alter its biological functions (15, 16, (18) (19) (20) (21) 31) . Thus, the structural basis for CCL5 oligomerization is unknown.
Significant efforts have been made to elucidate the structural basis of GAG binding to target proteins (3, 32, 33) . Such efforts reveal the structural diversity of GAGs, their target proteins, and the interaction interfaces between them. Mutational and structural studies have confirmed a role of the BBXB motif (basic/basic/x/basic residue) in CC chemokines in GAG binding, oligomerization, and receptor binding (4, 5, 14, 28, 34) . Structures of CCL3 and CCL4 oligomers, however, show that the BBXB motif is located at the interface between dimers of these chemokines (14) . Thus, oligomerization prevents the BBXB motif from binding GAG in the manner shown in the CCL5-GAG disaccharide structure (28) . Thus, how GAG binds CC chemokine oligomers and how chemokine oligomerization affects GAG binding remains unknown. Here, we combined crystallographic, SAXS, and mathematical modeling analyses to unveil the structural basis for CCL5 oligomerization at a physiological pH. We also solved the structures of CCL3 and CCL5 oligomers in complex with synthetic heparin to elucidate the molecular basis for the interaction of CC chemokine oligomers with GAG.
Results

Structural basis of CCL5 oligomerization:
To address the structural basis for CCL5 oligomerization, we sought to identify a crystallization condition for CCL5 at neutral pH (Table   S2 ). We found that the naturally occurring CCL5(4-68) variant of CCL5, in which three CCL5 N-terminal residues are deleted, displays dramatically reduced CCL5 precipitation without affecting formation of high MW oligomers. While CCL5(4-68) could be crystalized at an acidic pH, it also formed crystals at a pH of 7.0-8.0 that was temperature sensitive (optimal at 30 o C).
Heparins, a well-known class of GAGs, have disaccharide repeats of glucosamine-iduronic acid or glucosamine-glucuronic acid that have 48 possible combinations (33) . 23 of 48 possible repeats have been found in vivo. To determine a GAG-bound CCL5 oligomer structure, we used synthetic heparins that have one to four N,O6-disulfoglucosamine (SGN) and O2-sulfoiduronic acid (IDS) repeats ( Figure S1A ) (33, 35, 36) . The use of synthetic heparin eliminated the complexity and chemical heterogeneity of commercially available GAGs and allowed the formation of better diffracting crystals that had interpretable GAG density. We first solved the dimeric CCL5(4-68) structure crystallized at an acidic pH at 1.4Å resolution, then used it as a search model for molecular replacement. In conjunction with sulfur phasing, we solved the structure of CCL5(4-68) oligomer crystallized at a neutral pH in the presence and absence of heparin 8f, a synthetic heparin octasaccharide ( Figure S1A ) at 2.55Å and 3.05Å resolution, respectively (Table S2 ). The week-long dehydration of CCL5(4-68) crystals in the presence of 8f significantly improved diffraction quality.
The electron density of CCL5 is generally excellent except for the 4-10 N-terminal loop ( Figure S1B ). The structure of heparin-free CCL5(4-68) is a hexamer in an asymmetric unit ( Figure 1A ), while that of heparin 8f-bound CCL5(4-68) has nine monomers arranged as one and a half hexamers ( Figure S1C ). These hexameric structures are nearly identical ( Figure   S1D ). The CCL5 hexamer can be viewed as a complex of three CCL5 dimers. Within the hexamer, the CCL5 monomer has an expected structure: a N-terminal segment (aa [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] followed by a 3 10 helical turn (aa [21] [22] [23] , an anti-parallel three-stranded β-sheet (aa , and an α-helix (aa 55-68). The arrangement of CCL5 dimers is similar to dimeric CCL5 structures crystallized at low pH (Figure S1E-F) (25) (26) (27) (28) (29) (30) . However, the contacts between CCL5 dimers in our CCL5 oligomeric structure nicely explain how mutations affect CCL5 oligomerization and function. Between CCL5 dimers, E26 forms a salt bridge with R47 while E66 forms hydrogen bonds with T43 and R44 as well as a salt bridge with K45 ( Figure 1B ). This explains how the mutation of E66 or E26 to serine or alanine profoundly reduces CCL5 oligomerization and decreases its functionality while mutations at the 44 RKNR 47 BBXB motif also affect CCL5 oligomerization ( Figure S1G ) (15, 16, (18) (19) (20) (21) . This structure also explains how the A22K mutation enhances CCL5 oligomerization, since this lysine would form a hydrogen bond to N63 of the adjacent CCL5 monomer ( Figure S1H ) (31) . This structure can explain how an H23K mutation reduces CCL5 oligomerization by disrupting van der Waals contacts between H23 and N63 of the two CCL5 monomers (31).
The mechanism for forming double helical CCL5 oligomers is similar to that of CCL3 and CCL4 oligomers: The structure of CCL5(4-68) hexamer suggests that, like CCL3
and CCL4, charge and surface complementarity allow CCL5 dimers to come together and polymerize into rod-shaped double helical oligomers that are polydisperse in size ( Figure 1C -D) (14) . Residues that form hydrophilic interactions at the dimer-dimer interfaces are highly conserved between CCL3, CCL4 and CCL5, but not other CC chemokines ( Figure 1E , S1I-J).
This can explain why only these chemokines self-assemble into high MW oligomers. To probe whether wild type CCL5 forms rod-shaped oligomers in solution, we performed SAXS analysis of CCL5 (0.5-1 mg/mL) in buffer containing Tris-HCl (pH=8) and 500 mM NaCl to prevent CCL5 from precipitating ( Figure 2A ). If CCL5 oligomers were rod-shaped, the linearity over a range of scattering vectors in the plot of cross-section, Guinier rod would be expected. Indeed, the observed plot revealed linearity at q values ranging from 0.03 to 0.09 (Figure 2A inset ).
There are three available CCL5 oligomeric structures: a double helical rod based on our CCL5(4-68) structure (PDB=5CMD), a CCL5 structure derived from a hybrid method using NMR, SAXS and molecular simulation (PDB=2L9H), and P2-RANTES, which has enhanced the ability of CCL5 to inhibit HIV-1 infection due to its mutated N-terminal sequences (PDE=2VXW) (27, 29) . All of them are rod-shaped. We first generated a oligomer model from each of the three structures that best fit the experimental R g values and had χ values near 1 ( Figure 2A ). We then evaluated which model best fit the experimental cross-section R g value (R c ). We found that only the double helical CCL5 26mer derived from our CCL5(4-68) model fit the experimental scattering curves and R c value well ( Figure 2A ). While the CCL5 26mer offered the best fit among the three models, the predicted maximal dimension (D max ) of the CCL5 26mer (250 Å) deviated significantly from the observed D max value of CCL5 (350 Å, Figure 2A ). We rationalize that CCL5 follows a simple polymerization mechanism, and thus should exist as an equilibrium mixture of monomers, dimers, and oligomers of different lengths (14, 37) . Indeed, this model generated a pair distribution profile that fit well with the observed P(r) distribution (Figure 2A ). Together with existing mutational studies (15, 16, (18) (19) (20) (21) , we conclude that our double helical CCL5 oligomer model represents how CCL5 forms polydisperse oligomers in solution under physiological conditions ( Figure S1G ). This could also represent CCL5 filaments found on the surface of endothelial cells that are polydisperse in size (24) .
Under the same experimental conditions, we found that CCL3 had a much smaller R g (38Å) than wild type CCL5 (88Å) ( Figure 2B ). We speculate that the additional hydrophobic contacts in CCL5 could render CCL5 more prone to form high MW oligomers than CCL3
( Figure 1E ). The R g value of CCL3 was also much smaller than that of CCL3 observed in phosphate buffered saline (pH 7.2), which had an R g value of 130 Å (14) . This is likely because we used the higher NaCl concentration and slightly alkaline pH that could reduce the overall size of CCL3 oligomers. However, CCL3 retained its rod-shaped, polydisperse oligomeric structure ( Figure 2B ). We also performed a SAXS analysis of CCL5(4-68) under the same condition. However, the SAXS profile of CCL5(4-68) revealed significant aggregation, which precludes meaningful interpretation ( Figure S2B ).
Structure of heparin 8f-bound CCL5 and CCL3 oligomers:
To address how GAG binds CCL5 oligomers, we solved a heparin 8f-bound CCL5 hexamer structure. Anomalous signals confirmed the position of sulfate atoms in heparin 8f ( Figure S3A-B) . For each CCL5(4-68)
hexamer, two heparin 8f chains that contained three sugar moieties were clearly visible ( Figure   3A ). The trisaccharide of 8f binds a positively charged groove involving R17, K55, K56 and R59 of the CCL5(4-68) oligomer ( Figure 3B ). In addition to hydrogen bonds and van der Waals contacts, K55, K56 and R59 form a network of salt bridges with the sulfate groups of SGN-I, IDS-II, and SGN-III ( Figure 3C, 3D (18, 28, 34, 39) . This BBXB motif, however, is largely buried in our CCL5 oligomer structure, which prevents it from binding heparin ( Figure 3E, S3C) . Thus, our structure indicates that the 55 KKWVR 59 motif serves as the primary site to bind GAG when CCL5 is oligomerized. Our GAG-bound CCL5 structure suggested that the presence of heparin should significantly increase the propensity of CCL5 and CCL5(4-68) to form high MW aggregates. We probed the effect of heparin on CCL5 oligomerization by SAXS and found this to be the case ( Figure S2 ).
We have also solved a heparin 8f-bound CCL3 structure at 3.1Å resolution (Table S2 , Figure S4 ). The structure contains five CCL3 monomers arranged similarly to the heparin-free CCL3 oligomer (14) and four sugar moieties in the 8f-bound CCL3 structure ( Figure 4A, S4 ).
The CCL3 oligomers form a positively charged groove to bind heparin ( Figure 4B ). Taking advantage of the fact that the 45 KRSR 48 BBXB motif is only partially buried, K45 and R46 from two different BBXB motifs of CCL3 monomers form salt bridges and van der Waals contacts with SGN-I in heparin 8f ( Figure 4C ). In addition, Q19, N23, and K61 form salt bridges and hydrogen bonds with SGN-III and IDS-IV ( Figure 4C, 4D) . Furthermore, L66, D65 and Q22
form hydrophobic interactions with heparin 8f. Interestingly, most residues involved in the binding of heparin to CCL3 and CCL5 oligomers are not well conserved despite the high conservation of residues involved in oligomerization ( Figure 4E, 1E ).
Alternative CCL3 oligomer structure: While seeking conditions to crystallize heparin-bound CCL3, we found a new crystallization condition that formed in the presence of 8f. We optimized the condition without 8f and solved an alternative CCL3 oligomer structure at 2.55Å resolution ( Figure 5 , Table S2 , Figure S5A ). This structure had 10 CCL3 molecules in an asymmetric unit, which forms a double helical rod-shaped oligomer that is similar to the previously reported CCL3 oligomer structure (14) . However, four out of ten N-termini pass through the interface between CCL3 dimers and point outward towards the convex part of the CCL3 oligomer instead of pointing inward to the concave cavity of the CCL3 oligomer, as previously reported ( Figure 5A ) (14) . While the outward pointing N-termini do not alter the overall structures of CCL3 monomers or dimers (except the N-termini) ( Figure 5B), they push the CCL3 dimers apart, creating a larger gap (~3Å) between them ( Figure 5C, S5B) . As a result, salt bridges and hydrogen bonds between CCL3 dimers, including those between S33-Y15, E30-R18, D27-R46, and Y28-R48, are broken ( Figure 5C ). This leads to an overall loss of ~100Å 2 of contact surface between CCL3 dimers, thus likely reducing their affinity for each other ( Figure 5C , S5C). However, the outward pointing N-termini of CCL3 form hydrogen bonds between A1-S33, S2-S33 and N34-L3, which help stabilize this structure. Interestingly, this N-terminal protrusion profoundly increases the size of the positively charged pocket on the CCL3 surface, which could bind GAG ( Figure 5D ). This might explain why 8f facilitates the formation of this crystal form. However, no obvious extra density existed when CCL3 was cocrystallized with 8f. This could be due to the low occupancy constrained by a crystal lattice and/or crystallization condition.
Discussion
Based on our crystallographic, SAXS, and mathematical modeling analyses, we propose that CCL5 oligomerization follows a simple polymerization process to form rod-shaped double helical oligomers that are polydisperse in size ( Figure 6A ). Despite being very different in their isoelectric points and charge distribution, CCL5 has the same mechanism of oligomerization with CCL3 and CCL4 (14) . Our CCL5 oligomer structure explains existing CCL5 mutational data (15, 16, (18) (19) (20) (21) 31 ). Furthermore, it offers an alternative model to describe how CXCL4 enhances the arrest of CCL5-stimulated monocytes (40, 41) . Instead of hetero-dimerization between CCL5 and CXCL4 shown by NMR under an acidic condition (40), we propose that CXCL4 can form a hetero-oligomer with CCL5 ( Figure S6 ). CXCL4 was discovered based on its high affinity to heparin, and our modeling predicts that this hetero-oligomer would have altered electrostatic potential that could enhance GAG binding ( Figure   S6 ). In addition, the insertion of CXCL4 into CCL5 oligomer could also change the kinetics of Our structural studies also offer additional mechanisms for regulating the coupling of oligomerization and GAG binding. We found an N-terminal flipped conformation of CCL3 within CCL3 oligomers, which likely occurs naturally due to the flexible nature of CCL3 N-terminus.
This conformation has a reduced dimer-dimer interface, which should destabilize it relative to the non-flipped conformation and thus depolymerize more readily. This conformation, however, has a larger positively charged pocket so it could have a higher affinity for GAGs than the nonflipped conformation ( Figure 5D ). This is consistent with the fact that this crystal form is more readily formed when 8f was present. Thus, the presence of GAG would promote the dissociation of CCL3 oligomers by weakening the interaction between CCL3 dimers. This offers a means by which conformational switches can regulate CCL3 oligomerization and explains how CCL3 forms shorter oligomers in the presence of heparin (14) .
Our CCL5 oligomeric structure can, in part, explain how oligomerization affects CCL5
functions by affecting its proteolytic sensitivity ( Figure 6A ) (43) . Only monomeric CC chemokines bind and activate their respective cognate CCRs. However, they are highly susceptible to proteolysis, particularly at their N-termini, which is critical for receptor binding and activation (44) (45) (46) . In comparison, CC chemokine oligomers are resistant to proteases but receptor-binding incompetent since oligomerization buries CCR-binding sites. Thus, dimerization and oligomerization prolong the half-life of CC chemokines while reducing the effectiveness of these chemokines. The N-terminus of CCL5 can be cleaved by DPP IV and cathepsin G, thus altering the ability of CCL5 to activate its cognate receptors (43) . Our CCL5 oligomeric structure reveals that the CCL5 N-terminus is buried inside the concave surface of the oligomer, which should protect the oligomer from proteolytic inactivation. Oligomerization of CCL5 also buries substantial solvent-exposed areas. This should protect CCL5 from degradation by other extracellular proteases, e.g., tryptase (43) . We have proposed that the interplay between reversible oligomerization and protease-sensitivity makes CCL3 and CCL4 more effective chemoattractants over a longer range and thus encodes severity during infection or inflammation (14) ( Figure 6B ). This is applicable to CCL5 and other chemokine that can oligomerize, e.g., CCL2.
GAG binding in conjunction with oligomerization can profoundly affect the functions of CC chemokines. Similar to oligomerization, GAG binding could alter the chemotactic gradient of CC chemokines by modulating their sensitivity to proteases ( Figure 6C ). GAG could bring multiple CC chemokine oligomers together ( Figure 6C ). Consistent with this notion, analysis of symmetry-related molecules in our structure indicates that long chain GAGs can bring two CCL3 oligomers together ( Figure S4B-C) . GAG-mediated aggregation of CC chemokine oligomers could further increase the local concentration of CC chemokines to regulate the activation of cognate CCRs and the presentation of CC chemokines to circulating lymphocytes ( Figure 6C ). This would also promote the formation of high MW CC chemokine oligomers in the extracellular matrix and on cell surfaces ( Figure 6C ). The oligomerization of CC chemokines and novel GAG binding of CC chemokine oligomers could facilitate the aggregation of proteoglycan, e.g., CD44, which in turn promotes non-CCR mediated signaling, e.g., tyrosine phosphorylation ( Figure 6C ). Given the complexity of how chemokines recruit immune cells, which involves cell arrest and adhesion onto the endothelial cells, extravasation across blood vessels, and cell migration toward the source of the CC chemokines, future investigation will be required to elucidate how the GAG binding and oligomerization of CC chemokines are coupled to affect each step of chemokine-mediated cell recruitment under normal physiological and pathological settings.
Methods
Chemokine expression and purification, crystallization, data collection, and structure determination: The expression of thioreduxin-tagged CCL5, CCL5(4-68), and CCL3 in E. coli, the removal of thioreduxin-tag by enterokinase or TEV protease, and the purification of these chemokines by Ni-NTA, source-Q, and heparin columns are done similar to methods described previously (14, 47) . The octasaccharide heparin, MLZ-8f was synthesized as described (35) .
Crystals of CC chemokines in the presence and absence of heparin 8f were grown using hanging drop vapor diffusion and cryo-protected under the conditions listed in Table S2 . Diffraction data were collected at 100 K at beamline 19-ID or 19-BM at Advanced Photon Source, Argonne National Laboratory and processed with HKL3000 (48). Molecular replacement was done using PHASER (49) and structural refinement and rebuilding were performed with COOT (50) and PHENIX (51) (52) (53) . Further details are provided in supplemental methods.
SAXS Data Acquisition and Analysis -SAXS data were collected at the BioCAT/18ID
beamline at Advanced Photon Source, Argonne National Laboratory. Chemokine (0.6 mg/ml CCL5, 0.9 mg/ml CCL5(4-68), and 1 mg/ml CCL3) in the presence or absence of 1-10 μg/ml heparin (Alfa Aesar) in the buffer containing 20 mM Tris-HCl (pH 8.0), 500 mM NaCl, 1mM
EDTA and 1mM β-mercaptoethanol was used for data collection. ATSAS package, Primus, and Crysol were used for data reduction and analysis (53, 54) . A simple scheme for polymerization assuming equal probability of binding or unbinding between dimers independent of location was used to generate a model of oligomer size distribution to fit the SAXS data (14, 37) . Further details are provided in supplemental methods. Distance from secretion site
